William Blair Has Negative Estimate for KROS Q2 Earnings

Keros Therapeutics, Inc. (NASDAQ:KROS) – Investment analysts at William Blair dropped their Q2 2025 earnings per share estimates for Keros Therapeutics in a research report issued to clients and investors on Tuesday, May 6th. William Blair analyst M. Phipps now forecasts that the company will earn ($1.08) per share for the quarter, down from their prior forecast of ($0.81). The consensus estimate for Keros Therapeutics’ current full-year earnings is ($4.74) per share. William Blair also issued estimates for Keros Therapeutics’ Q3 2025 earnings at ($0.83) EPS, Q4 2025 earnings at ($0.74) EPS, FY2025 earnings at $0.51 EPS, Q1 2026 earnings at ($0.77) EPS, Q2 2026 earnings at ($0.78) EPS, Q3 2026 earnings at ($0.78) EPS, Q4 2026 earnings at ($0.78) EPS, FY2026 earnings at ($3.11) EPS, FY2027 earnings at ($2.90) EPS and FY2028 earnings at ($2.63) EPS.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings results on Tuesday, May 6th. The company reported $3.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.01) by $3.63. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The company had revenue of $211.25 million during the quarter, compared to the consensus estimate of $84.62 million. During the same period last year, the company earned ($1.21) earnings per share.

Several other brokerages have also recently issued reports on KROS. Truist Financial decreased their price objective on Keros Therapeutics from $43.00 to $25.00 and set a “buy” rating for the company in a report on Wednesday, April 9th. HC Wainwright dropped their price objective on shares of Keros Therapeutics from $40.00 to $25.00 and set a “buy” rating on the stock in a research note on Thursday. Cantor Fitzgerald cut shares of Keros Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Tuesday, January 21st. Piper Sandler dropped their price target on shares of Keros Therapeutics from $40.00 to $15.00 and set an “overweight” rating on the stock in a research report on Friday, January 17th. Finally, Wedbush reiterated a “neutral” rating and issued a $15.00 price objective on shares of Keros Therapeutics in a research report on Tuesday, April 1st. Six equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $38.67.

Keros Therapeutics Trading Down 2.6 %

Keros Therapeutics stock opened at $13.65 on Friday. The firm has a 50-day moving average price of $12.20 and a 200-day moving average price of $24.47. Keros Therapeutics has a 12-month low of $9.12 and a 12-month high of $72.37. The firm has a market capitalization of $554.39 million, a PE ratio of -2.62 and a beta of 1.32.

Institutional Trading of Keros Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. GAMMA Investing LLC lifted its holdings in shares of Keros Therapeutics by 7,690.3% in the 1st quarter. GAMMA Investing LLC now owns 2,415 shares of the company’s stock worth $237,000 after acquiring an additional 2,384 shares during the last quarter. FNY Investment Advisers LLC acquired a new stake in shares of Keros Therapeutics in the first quarter valued at $25,000. CWM LLC raised its holdings in shares of Keros Therapeutics by 10,157.7% in the 1st quarter. CWM LLC now owns 2,667 shares of the company’s stock valued at $27,000 after buying an additional 2,641 shares during the period. AlphaQuest LLC boosted its holdings in Keros Therapeutics by 469.0% during the 4th quarter. AlphaQuest LLC now owns 3,596 shares of the company’s stock valued at $57,000 after acquiring an additional 2,964 shares during the period. Finally, Virtus ETF Advisers LLC increased its stake in Keros Therapeutics by 107.5% during the fourth quarter. Virtus ETF Advisers LLC now owns 3,857 shares of the company’s stock worth $61,000 after purchasing an additional 1,998 shares during the period. Institutional investors and hedge funds own 71.56% of the company’s stock.

Insiders Place Their Bets

In other news, major shareholder Adar1 Capital Management, Llc acquired 934,258 shares of the company’s stock in a transaction that occurred on Wednesday, April 9th. The stock was purchased at an average price of $10.13 per share, with a total value of $9,464,033.54. Following the completion of the acquisition, the insider now owns 4,392,737 shares of the company’s stock, valued at $44,498,425.81. This trade represents a 27.01 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 20.60% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.